You are here

Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

Last updated on February 21, 2019

FOR MORE INFORMATION
Study Location
Healthcare Corporation MEDOC Medical Dock&Clinic
Nagoya, Aichi, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension, Hypercholesterolemia, Angina Pectoris
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject with both hypertension and hypercholesterolemia must meet the following (1),
and the following (2) or (3):

- (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2,
and Subjects with well controlled BP value (BP value

- (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2

- (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3
months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C TG

- Subject with both angina pectoris and hypercholesterolemia must meet the following
(1), and the following (2) or (3):

- (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2,
and who meet the following criteria; Subjects with well controlled BP value (BP value

- (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2

- (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3
months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C TG

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects who need three or more multi-antihypertensive therapies to achieve the target
BP level or uncontrolled status of hypertension at Week 0 (V1); the target BP level is
defined as systolic blood pressure

- Uncontrolled or uncontrollable status of hypercholesterolemia at Week -2; A LDL-C ?
160 mg/dL even though Atorvastatine 10 mg has administrated

NCT01190007
Pfizer
Completed
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hypertension, High Blood Pressure
NCT00355589
All Genders
18+
Years
Multiple Sites
Primary Open Angle (POAG) Glaucoma, Ocular Hypertension
NCT00230763
All Genders
18+
Years
Multiple Sites
Open-Angle Glaucoma, Ocular Hypertension
NCT00159653
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now